Latest news with #NeuroRestore
Yahoo
03-06-2025
- Business
- Yahoo
AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on June 10
STOCKHOLM, SE / / June 3, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company's CEO Martin Jönsson will present at Stora Aktiedagarna in Stockholm, Sweden, hosted by Aktiespararna, at 08:50 CET on June 10. In his presentation, Martin Jönsson will highlight the company's project portfolio and drug candidates from the research platforms NeuroRestore ® , Alzstatin ® and Painless. The presentation will be followed by a Q&A led by Aktiespararna's moderator. The live broadcast is available via the following link: The presentation will also be available on the company's website afterwards: For more information about the event and to register to attend the Birger Jarl Conference in Stockholm, please see here: Event time: June 10, 08:00 CET - June 11, 19:00 CETPresentation time: June 10, 08:50 CETVenue: Birger Jarl Konferens, Birger Jarlsgatan 61 A, Stockholm, Sweden For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . Image Attachments Martin Jönsson CEO AlzeCure Pharma Attachments AlzeCure Pharma to present at Stora Aktiedagarna in Stockholm on June 10 SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
11-05-2025
- Health
- CBS News
Injuries left them paralyzed. An early promising clinical trial is helping them walk short distances again.
For those who've suffered a traumatic spinal cord injury and are paralyzed, there's rarely encouraging news, which is why what's happening in early clinical trials in a research lab in Lausanne, Switzerland is so remarkable. A renowned French neuroscientist, Gregoire Courtine, and Swiss neurosurgeon, Dr. Jocelyne Bloch, have implanted a small stimulation device on the spine of paralyzed patients, helping them once again stand up and walk. What's even more surprising is their newest innovation, which uses an implant in the skull that enables patients to move their paralyzed legs or arms, just by thinking about it. When we visited their lab, NeuroRestore, in March, they were working with a 39-year-old woman whose spinal cord was severed six and a half years ago. She'd been told she'd never walk again. Marta Carsteanu-Dombi is the most severely paralyzed patient who's enrolled in this clinical trial at NeuroRestore to regain mobility in her legs. She has no feeling below her waist and isn't able to keep her balance. Just sitting up on her own is a challenge. In 2018, Marta was a new mom, working at a German tech company, when she began training with her husband for an IronMan competition. She was in the best shape of her life, but during the bike portion of the race she suffered a devastating accident. Anderson Cooper: You were found– Marta Carsteanu-Dombi: Near a tree. Anderson Cooper: --near a tree? Marta Carsteanu-Dombi: Yes. So– Anderson Cooper: And your back hit the tree. Marta Carsteanu-Dombi: We're hypothesizing what happened, right, 'cause nobody saw me. So, I must have had a pretty tough collision because my spine basically broke, like, two dimensions. Marta Carsteanu-Dombi 60 Minutes Her spinal cord injury was so severe doctors said there was no sign of nerve connections left to her lower body. She'd also broken eight ribs, punctured her lungs, and was bleeding internally. She needed emergency surgery and doctors told her family she might not survive. Anderson Cooper: You came out of the surgery-- I understand you wrote a message to your mom. Marta Carsteanu-Dombi: So the surgery took about seven to eight hours, and I was intubated; I could not talk. And my mom, you can imagine, was in tears. And I just wrote to her, "I'm strong." That strength has been tested. Marta spent 10 days in intensive care and four and a half months in a rehab hospital learning to adapt to her new life in a wheelchair. Anderson Cooper: Traditionally, if someone gets a spinal cord injury, what are the treatment options for them? Jocelyne Bloch: You have to do a little bit of physiotherapy, get into a wheelchair and then you go back home. And that's all. Anderson Cooper: That's it? Jocelyne Bloch: That's it. And that was for many years the only option. Dr. Jocelyne Bloch and Gregoire Courtine have been at the forefront of researchers trying to expand those options since 2012. Their lab, near Lake Geneva, is a collaboration between the Swiss Federal Institute of Technology, Switzerland's MIT, and the Lausanne University hospital. That's where they've implanted eight paralyzed patients with a device that allows them to stimulate their spinal cords, enabling them to stand, take steps with a walker, and lift weights. Some can even climb stairs. They use a button to activate the stimulation. And now, thanks to Courtine and Bloch's latest technology, five other patients can move their paralyzed limbs using their own thoughts. It's called a digital bridge, and it wirelessly connects a patient's brain to their spinal cord stimulator. Gregoire Courtine: Normally there is a-- a direct communication between the brain and the spinal cord. Anderson Cooper: For me to walk, my brain just automatically tells my legs to walk? Jocelyne Bloch: Uh-huh. French neuroscientist Gregoire Courtine and Swiss neurosurgeon Dr. Jocelyne Bloch 60 Minutes Gregoire Courtine: But because of the spinal cord injury the signal is interrupted. So we are aiming to bridge-- bypass the injury by having a direct digital connection between the brain and the region of the spinal cord that control leg movement. To do that, Dr. Bloch implants a small titanium device, originally developed by a French research institute, in the patient's skull directly over their motor cortex, the area of the brain responsible for controlling movement. Gregoire Courtine: You see you have the 64 electrodes. Anderson Cooper: And so each of these is what? Jocelyne Bloch: It's electrode that are recording populations of neurons underneath. And you can immediately see which one are the best correlated to certain movements. Gregoire Courtine: Like the hip is here, and then the knee is here, and then the ankle is here, etc. Jocelyne Bloch: Yeah, yeah. When a patient thinks about moving a limb, those electrodes record the brain's activity. Then a computer uses artificial intelligence to translate the recordings into instructions for the stimulation device implanted on the spinal cord. That device sends electrical pulses activating muscles in the legs or arms. All of it happens in about half a second. Gert-Jan Oskam was the first person to get the "digital bridge" four years ago after he was paralyzed in a bike accident. We met him for a walk by Lake Geneva. Anderson Cooper: So now the stimulation is on? Gert-Jan Oskam: Now it's on, yes. Anderson Cooper: Do you feel it at all in your body? Gert-Jan Oskam: I do feel a little tingling sensation from the stimulation with my brain. Dutch man Gert-Jan Oskam can now walk up to 450 feet. His headpiece powers the implant in his skull, and on his walker is the computer. It's cumbersome and tiring, physically and mentally, but he can walk up to 450 feet. Anderson Cooper: It's incredible to me though that you can continue talking with me even though this machine is reading the signals from your brain. Gert-Jan Oskam: It's able to discriminate walking and talking at the same time. That's-- that's incredible. Anderson Cooper: For somebody who has not been able to control their movements, to suddenly be able to control their movement, I mean, that's-- Jocelyne Bloch: Yeah. There is this initial phase of surprise, you know, when they realize that it's-- they are giving the order and it's happening. You know? Gregoire Courtine: They are like, "Did I do that? Like, is it me or you actually stimulate it, no?" I say, "No, you did it." Anderson Cooper: They think you're pressing a button somewhere and doing it? Jocelyne Bloch: Yeah, yeah, yeah. Gregoire Courtine: They don't understand 'cause they've been paralyzed for so many years. Marta got the digital bridge implanted in September. She's worked with a team of engineers and physical therapists to figure out how much electrical stimulation is needed to move her legs. Gregoire Courtine: Nice. Marta Carsteanu-Dombi: Yeah, it's good. Gregoire Courtine: And up. Anderson Cooper: So that's the stimulation-- the electrical stimulation is making the leg move. Gregoire Courtine: Yeah, Marta is completely paralyzed. But Marta's also had to teach herself to think about moving the exact same way every time, so the AI can recognize her thoughts. She practiced at first with this avatar. Anderson Cooper: You have to relearn or rethink how to walk. Marta Carsteanu-Dombi: Exactly. So we were experimenting a little bit. What do I think about? Is it I think about the hip being contracted? Do I think about the knee lifting up? Do I think about the ankle? To show us how she does that, they disconnected her skull implant from her spinal cord stimulator and connected it to this exoskeleton. Anderson Cooper: You can control this with your thoughts right now. Marta Carsteanu-Dombi: Yeah. If I want to do a right movement, right hip flexion, it does a right hip flexion. Anderson Cooper: You're not pressing any buttons– Marta Carsteanu-Dombi: No. Anderson Cooper: --or anything. You're just thinking. Marta Carsteanu-Dombi: Sure. Anderson Cooper: Can you look at me without looking at it and just- Marta Carsteanu-Dombi: Do a right one? Yes. I think it works. Anderson Cooper: Yeah. Gregoire Courtine: It does work. Marta Carsteanu-Dombi 60 Minutes After training with the digital bridge for just two days, Dr. Jocelyne Bloch and Gregoire Courtine, or G as Marta calls him, put her to the test- eager to see if she could take some steps. Marta Carsteanu-Dombi: Jocelyne and G come in and it's like, "Okay, show off. So what can you do?" Anderson Cooper: They said, "Show off?" Marta Carsteanu-Dombi: Yeah, yeah. Anderson Cooper: Were you ready to show off? Marta Carsteanu-Dombi: I did not know if I'm able to show off. This was the thing. Using a harness to support about half her body weight and physical therapists to help place her feet on the ground, Marta took her first steps. Despite having no sensation below her waist, she was able to move her paralyzed legs with her thoughts. Anderson Cooper: What was that like? Marta Carsteanu-Dombi: Gaining some superpower. A power that I did not have before. And now with these implants, you know, it's-- I'm a real Ironwoman. When we were there in March, Marta wasn't able to walk on her own yet, but she said she'd already regained something she'd lost. Marta Carsteanu-Dombi: It's giving me my perspective back. Standing up again and looking people in the eye, that's different. Anderson Cooper: A difference in how you think about yourself or in how others see you– Marta Carsteanu-Dombi: Both– Anderson Cooper: --or how you interact in the world? Marta Carsteanu-Dombi: Everything. Everything. Arnaud Robert: You leave the hospital on your wheelchair and you notice the different looks. Anderson Cooper: Right away you noticed? Arnaud Robert: Yeah. Scared looks. Also, a lot of smiles that are a little bit too long. Arnaud Robert 60 Minutes Those well-meaning smiles reminded Arnaud Robert, who's quadriplegic, how much his life had changed. A Swiss journalist, he'd spent decades traveling the world, but three years ago he slipped on a patch of ice and was instantly paralyzed from the neck down. He regained some function in his right arm with physical therapy, but wanted to see if the digital bridge could help him with his left. Anderson Cooper: Opening and closing the hand is far more complex than walking? Gregoire Courtine: It is, because of the possibility to access a different muscle individually. Jocelyne Bloch: The hand is tricky with all these different little muscles. It's very subtle. But after surgery and training at Courtine and Bloch's lab for eight months, he was able to use his left hand to help hold a glass and type. Arnaud Robert: Even to be able to move my fingers, this is something that I couldn't do. And, of course, moving the-- the arm like that, this is something that I couldn't do either. Anderson Cooper: That's incredible. Arnaud Robert: It's really incredible. I mean, I don't want to pretend that I'm using this left arm on a daily base. There is a long, long way to get it functional for every quadriplegic in the world. But it was certainly a success, because I see that I can do things that I wouldn't-- I was not able to do before. But something else has happened as well: after using the digital bridge over time, both Arnaud and Gert-Jan have improved their ability to move their paralyzed limbs, even when the system is turned off. Anderson Cooper: How is that possible? What happened? Jocelyne Bloch: That was also our questions. And we could not do much in a human being to understand it. Since it wasn't possible for them to see the changes in their patients' spinal cords at a microscopic level, they did studies in animals to understand what was happening. Gregoire Courtine: What we understood was completely unexpected, that this training enabled the growth of new nerve connection. So new nerves started growing. And they grow on one very specific type of neuron that is uniquely equipped to repair the central nervous system. Jocelyne Bloch: So we also observed that the less the severity of the spinal cord lesion is, the, the better the regrowth happens. You know? If it's a complete spinal cord injury, it will be hard to regrow. But, indeed, there is something happening. How well the digital bridge works still needs to be studied in a lot more patients. They hope to launch clinical trials in the U.S. in the next two to three years. The FDA has already designated it as a breakthrough device, which will prioritize the review process, and Courtine and Bloch have co-founded a company called Onward Medical to bring this technology out of the lab, making it faster, smaller, and widely available. Marta Carsteanu-Dombi: It's not changing my everyday in ways people might think, "Oh, she's-- she's getting back her life she had before." So as long as it makes me feel good, that I can stand up and hug my husband or hug somebody that I love, that means a lot. Anderson Cooper: What's your goal? Marta Carsteanu-Dombi: To go out in the park, and just stand up and do some steps with my family. It's not a stroll in the park how it would look for most other people. But for me it's just good enough to make me happy. After six months of hard work, just before Marta was to return to her family, she did what doctors years ago told her she never would: she took a few steps. No harness to hold her, just her walker and her iron will. Produced by Nichole Marks. Associate producer, John Gallen. Broadcast associate, Grace Conley. Edited by Peter M. Berman.
CBS News
11-05-2025
- Health
- CBS News
Paralyzed woman feels like "real Ironwoman" after implants help her take steps again
Marta Carsteanu-Dombi was in the best shape of her life when a bike accident during a 2018 Ironman race left her paralyzed, robbing her of the ability to walk. Her spinal cord injury was so severe that doctors told her there was no sign of nerve connections left to her lower body. She also had eight broken ribs, punctured lungs and was bleeding internally. Carsteanu-Dombi, 39, was told by doctors she'd never walk again, but an early clinical trial in Switzerland gave her new hope. With the help of the "digital bridge" technology, which wirelessly connects an implant on top of her brain to a spinal cord stimulator, and months of training, she was able to take a few steps on her own: no harness to hold her, just her walker and her iron will. She describes it as gaining a superpower. "And now, with these implants, I'm a real Ironwoman," she said. Innovative technology When someone gets a traumatic spinal cord injury and is paralyzed, there isn't much doctors can offer. Patients do physical therapy and learn to adapt to life in a wheelchair. It was, for many years, the only option, said Swiss neurosurgeon Dr. Jocelyne Bloch. French neuroscientist Gregoire Courtine and Swiss neurosurgeon Dr. Jocelyne Bloch 60 Minutes Dr. Bloch and French neuroscientist Gregoire Courtine have been at the forefront of researchers around the world trying to expand those options since 2012. Their lab, NeuroRestore, near Lake Geneva in Lausanne, Switzerland, is a collaboration between the Swiss Federal Institute of Technology, Switzerland's equivalent of MIT, and the Lausanne University Hospital. That's where they've implanted eight paralyzed patients with a device that allows them to stimulate their spinal cords, enabling them to stand, take steps with a walker, and lift weights. The patients use a button to activate the stimulation. Thanks to Courtine and Bloch's latest technology, which they call a digital bridge, five other patients can now move their paralyzed limbs using their own thoughts. Normally, there's direct communication between the brain and spinal cord, but a severe spinal cord injury disrupts that signal. "So we are aiming to bridge - bypass the injury - by having a direct digital connection between the brain and the region of the spinal cord that control[s] leg movement," Courtine said. To do that, Dr. Bloch implants a small titanium device, originally developed by a French research institute, in the patient's skull, directly over their motor cortex, the area of the brain responsible for controlling movement. The device has 64 electrodes. When a patient thinks about moving a limb, those electrodes record the brain's activity. Then, a computer uses artificial intelligence to translate the recordings into instructions for the stimulation device implanted on the spinal cord. That device sends electrical pulses activating muscles in the legs or arms. All of it happens in about half a second. Dutch man Gert-Jan Oskam can now walk up to 450 feet. Dutch man Gert-Jan Oskam, who four years ago became the first person to get the digital bridge, showed how it works on a walk by Lake Geneva with 60 Minutes. He wore a headpiece that powers the implant in his skull. The computer was on his walker. It's cumbersome and tiring, both physically and mentally, but he can walk up to 450 feet. "It's able to discriminate [between] walking and talking at the same time," Oskam said. "That's incredible." The most severely paralyzed patient enrolled in the clinical trial for walking Courtine and Bloch were working with Carsteanu-Dombi, the most severely paralyzed patient enrolled in the clinical trial to regain mobility in her legs, when 60 Minutes visited in March. At that point, it had been more than six years since her spinal cord was severed during the bike portion of an Ironman race. She was found near a tree. Nobody saw the accident that left her paralyzed. "I must have had a pretty tough collision because my spine basically broke, like, two dimensions," Carsteanu-Dombi said of the 2018 accident. Carsteanu-Dombi was intubated when she woke up from surgery and could not talk, so she wrote a message to her mom: "I'm strong." That strength has been tested. Carsteanu-Dombi spent 10 days in intensive care and more than four months in a rehab hospital learning to adapt to her new life in a wheelchair. Carsteanu-Dombi has no feeling below her waist, and isn't able to keep her balance. Sitting up on her own is a challenge. She had the digital bridge implanted in September, and has worked with a team of engineers and physical therapists to figure out how much electrical stimulation is needed to move her legs. Carsteanu-Dombi also had to teach herself to think about moving the exact same way every time, so that the AI can recognize her thoughts. She practiced at first with an avatar and had to relearn what she thinks about when it comes to walking: is it about the hip contracting or the knee lifting? After training with the digital bridge for just two days, Dr. Bloch and Courtine put her to the test, eager to see if she could take some steps. They told her to show off. Marta Carsteanu-Dombi and Anderson Cooper 60 Minutes "I did not know if I'm able to show off," Carsteanu-Dombi said. "This was the thing." But show off she did. With a harness to support about half her body weight and physical therapists to help place her feet on the ground, Carsteanu-Dombi took her first steps using the digital bridge. Despite having no sensation below her waist, she was able to move her paralyzed legs with her thoughts. "It's not changing my everyday in ways people might think, 'Oh, she's getting back her life she had before'," Carsteanu-Dombi said. "As long as it makes me feel good, that I can stand up and hug my husband or hug somebody that I love, that means a lot." The digital bridge and restoring arm movement Swiss journalist Arnaud Robert traveled the world for decades but three years ago he slipped on a patch of ice and was instantly paralyzed from the neck down. Robert regained some function in his right arm with physical therapy and wanted to see if the digital bridge could help him with his left arm. It's a challenge because opening and closing a hand is more complex than walking, Courtine said. "The hand is tricky with all these different little muscles. It's very subtle," Dr. Bloch said. But after surgery and training at Courtine and Bloch's lab for eight months, Robert was able to use his left hand to help hold a glass and type. "There is a long, long way to get it functional for every quadriplegic in the world. But it was certainly a success, because I see that I can do things that I wouldn't, I was not able to do before," Robert said. Arnaud Robert 60 Minutes After using the digital bridge over time, both Robert and Oskam have improved their ability to move their paralyzed limbs even when the system is turned off. Since it wasn't possible for Courtine and Bloch to see the changes in their patients' spinal cords at a microscopic level, they did studies in animals to try to understand what was happening. What they believe happened was completely unexpected. The training enabled the growth of new nerve connections, Courtine said. "New nerves started growing," he said. "And they grow on one very specific type of neuron that is uniquely equipped to repair the central nervous system." The less severe the spinal cord lesion is, the better the regrowth happens, Bloch added. "If it's a complete spinal cord injury, it will be hard to regrow. But, indeed, there is something happening," she said. Hopes for restoring movement in the future How well the digital bridge works still needs to be studied in a lot more patients. Courtine and Bloch hope to launch clinical trials in the United States in the next two to three years. The Food and Drug Administration has already designated the digital bridge as a breakthrough device, which will prioritize the review process. In 2014, Courtine and Bloch co-founded a company called Onward Medical to bring this technology out of the lab, making it faster, smaller, and widely available. As for Carsteanu-Dombi, she has a goal of her own: to visit a park with her family, and take some steps with them. "It's not a stroll in the park, how it would look for most other people," she said. "But for me, it's just good enough to make me happy."
Yahoo
07-04-2025
- Health
- Yahoo
New Data Bolstering the Anti-inflammatory Effect of NeuroRestore ACD856 Presented at Alzheimer's Conference
STOCKHOLM, SE / / April 7, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, announced today that the company's presentation at the AD/PD 2025 scientific conference is now available in its entirety on the company's website. The presentation includes new preclinical data with the company's lead drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease. The presentation, titled Further investigation on the immunomodulatory and anti-inflammatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer's disease , which was presented at the International Conference on Alzheimer's, Parkinson's and Related Neurological Diseases (AD/PD 2025) in Vienna, Austria, was held by Dr. Gunnar Nordvall, Head of Chemistry at AlzeCure Pharma. The new preclinical data presented show that ACD856, the lead drug candidate in the NeuroRestore project, significantly reduced levels of several well-known inflammatory markers such as IL-6, PGE2 and COX in a preclinical model of neuroinflammation. The model uses so-called microglia, which are immune cells found in the brain and are thought to play a very important role in the disease process in Alzheimer's disease. "These new findings suggest that ACD856, along with its memory-enhancing and disease-modifying effects, may reduce neuroinflammation, a critical factor in the development of Alzheimer's, which could further delay the disease's progression," said Gunnar Nordvall, Head of Chemistry at AlzeCure Pharma. ACD856 is a positive modulator of both NGF/TrkA and BDNF/TrkB-mediated signaling that has been shown in preclinical studies to enhance communication between neurons and improve cognitive function, including learning and memory. Previous preclinical results from AlzeCure show that the compound also has neuroprotective, anti-inflammatory and disease-modifying effects in several different models. The unique pharmacological mechanism of NeuroRestore also enables multiple indications, such as Alzheimer's and Parkinson's disease, but also depression. ACD856 is a first-in-class drug candidate for Alzheimer's disease and is now being prepared for upcoming Phase II clinical trials in patients, which is financially supported by the European Innovation Council, via an EIC Accelerator grant of €2.5m. "These are very good results that add to the previous positive data for NeuroRestore ACD856 and further strengthen our commercial opportunities for this promising compound in areas with very high medical needs," said Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and the poster are available on AlzeCure's website ( ). For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . About NeuroRestoreNeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive ability is impaired, e.g. Alzheimer's Disease, sleep apnea, traumatic brain injury and Parkinson's disease. NeuroRestore stimulates several important signaling pathways in the brain, which among other things leads to improved cognition. Preclinical studies with NeuroRestore have shown that AlzeCure's drug candidates enhance communication between the nerve cells and improve cognitive ability. The NeuroRestore substances are so called Trk-PAMs which stimulate specific signaling pathways in the central nervous system known as neurotrophins, the most well-known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). The levels of NGF and BDNF are disturbed in several disease states and the signaling is reduced. The impaired function impairs communication between the synapses, i.e. the contact surfaces of the nerve endings, as well as reducing the possibility of survival for the nerve cells, which gives rise to the cognitive impairments. Neurotrophins play a crucial role for the function of nerve cells, and a disturbed function of BDNF has a strong genetic link to impaired cognitive ability in several different diseases, such as Alzheimer's, Parkinson's disease, traumatic brain injury and sleep disorders. There is also a link between BDNF signaling and depression, something that has been further strengthened in recent years. In addition to cognitive-enhancing effects, new preclinical data also show that NeuroRestore substances have a positive effect on mitochondrial function and display neuroprotective as well as anti-inflammatory effects, which could indicate potential disease-modifying effects. The leading drug candidate in the platform, ACD856, has recently completed clinical phase I studies and demonstrated positive effects there that support continued development of the program and are being prepared for phase 2. Read more at: About Alzheimer's diseaseAlzheimer's disease is the most common form of dementia, affecting approximately 55 million people worldwide, and the number is estimated to triple in the next 30 years if nothing is done. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases are estimated to about 1,300 billion USD globally in 2019. Given the lack of both effective symptomatic treatments and disease modifying treatments, including preventive treaments, the need for new effective therapies is acute. The few approved drugs on the European market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than $15 billion in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about SEK 63 billion yearly, which is more than for cancer and cardiovascular diseases combined. Image Attachments Martin Jönsson And Gunnar Nordvall AlzeCure Pharma Attachments New data bolstering the anti-inflammatory effect of NeuroRestore ACD856 presented at Alzheimer's conference SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
01-04-2025
- Business
- Yahoo
AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8
STOCKHOLM, SE / / April 1, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company is participating at Redeye Theme: Alzheimer & Parkinsons on April 8, 10:55am, when CEO Martin Jönsson presents the company and its pipeline within Alzheimer's. Watch the livestream via The session will also be available afterwards on AlzeCure's company page at Redeye , and on AlzeCure's website . Time: 10.30am - 12.00pm CET, April 8Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . Image Attachments Martin Jönsson CEO AlzeCure Pharma Attachments AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8 SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire Sign in to access your portfolio
